ESTRO 2024 - Abstract Book

S2019

Clinical - Paediatric

ESTRO 2024

The dose and dose-volume effects reported here can be used to better inform contemporary RT planning for newly diagnosed children. These data could be used to inform colorectal cancer screening guidelines in the population to better stratify those at the highest risk of colorectal SMN, i.e., high RT dose to large volumes of the colorectum (V30>80%), mean colorectal doses ≥10Gy and procarbazine dose >4.0 mg/m 2 .

Keywords: subsequent colorectal cancer, dose-response model

548

Proffered Paper

Outcome of childhood-onset craniopharyngioma treated at the West German Proton Therapy Centre Essen

Martin Bischoff 1,2 , Dalia Ahmad Khalil 1 , Sabine Frisch 1 , Christine Hansel 1 , Benjamin Koska 1 , Stephan Tippelt 3 , Rolf Dieter Kortmann 4 , Brigitte Bison 5 , Carsten Friedrich 6 , Hermann L Müller 6 , Beate Timmermann 1,7 1 University Hospital Essen, West German Proton Therapy Centre Essen (WPE), Department of Particle Therapy, 45147 Essen, Germany. 2 Ruhr-University Bochum, Marien Hospital Herne, Department of Radiation Oncology, 44625 Herne, Germany. 3 University Hospital Essen, Department of Pediatrics III, Pediatric Oncology and Hematology, 45147 Essen, Germany. 4 University of Leipzig, Department of Radiation Oncology, 04103 Leipzig, Germany. 5 University of Augsburg, Faculty of Medicine, Diagnostic and Interventional Neuroradiology, 86156 Augsburg, Germany. 6 Carl von Ossietzky University Oldenburg, Klinikum Oldenburg AöR, , University Children’s Hospital, Department of Paediatrics and Paediatric Haematology/Oncology, 26133 Oldenburg, Germany. 7 German Cancer Consortium, (DKTK), 45147 Essen, Germany

Purpose/Objective:

Craniopharyngiomas (CPs) are rare, non-malignant tumors that often cause significant health problems due to their proximity to sensitive structures. We report early data on survival outcome and late adverse events after surgery and proton beam therapy (PBT) in childhood CPs.

Material/Methods:

Between August 2013 and June 2022, 74 children with CP and <18 years at time of PBT (42 girls, 32 boys) were included in this analysis. All were enrolled in the prospective registry study “KiProReg” (DRKS0000536). The median age at PBT was 9.2 years (range, 3.4-17.5 years). 91.9% of patients had adamantinomatous CPs. One patient was diagnosed with a single implantation metastasis in the left ventricle besides the primary disease at the time of PBT. Treatment approaches were according to the GPOH (German Society for Pediatric Oncology and Hematology) trial craniopharyngioma 2007 and 2019 registry. Median applied dose was 54 Gy (RBE) with 1.8 Gy fraction dose. PBT was in 85.1% PBS (Pencil Beam Scanning). Besides uniform scanning (US), or a combination of PBS and US was used. Four patients received irradiation with PBS plus static aperture. The neuroendocrine status, laboratory parameters and/or provocation tests were evaluated in addition to clinical course parameters. The obesity level was evaluated using the age- and gender-adjusted BMI-standard deviation score (BMI-SDS). Adverse events were documented according to CTCAE v4.0 after PBT.